Yahoo
OTC Markets OTCPK - Delayed Quote USD

Sartorius Stedim Biotech S.A. (SRTOY)

24.81 -0.51 (-2.01%)
At close: October 30 at 4:00:00 PM EDT
Chart Range Bar
Loading chart for SRTOY
  • Previous Close 25.32
  • Open 24.81
  • Bid 24.69 x 30000
  • Ask 24.81 x 92700
  • Day's Range 24.81 - 24.81
  • 52 Week Range 17.25 - 26.54
  • Volume 300
  • Avg. Volume 24,789
  • Market Cap (intraday) 24.138B
  • Beta (5Y Monthly) 1.11
  • PE Ratio (TTM) 63.62
  • EPS (TTM) 0.39
  • Earnings Date --
  • Forward Dividend & Yield 0.08 (0.32%)
  • Ex-Dividend Date Apr 1, 2026
  • 1y Target Est --

Sartorius Stedim Biotech S.A. engages in the production and sale of instruments and consumables for the biopharmaceutical industry worldwide. The company offers various products, such as cell lines; cell culture media; bioreactors; reagents; advanced therapies; and a range of products for separation, purification, and concentration processes, as well as products and systems for storage and transportation of intermediate and finished biological products. It also provides fluid management services; biolayer interferometry instruments; microbiology testing, sterility testing, and air monitoring instruments; pipette products; sensors and analyzers; screening instruments; biomolecule analysis tools; batch liquid chromatography systems; lab data and fleet management software; live cell imaging and analysis; surface plasmon resonance solutions; water purification systems; and weighing products. In addition, the company offers data analytics software; process automation platform and software; and transfection reagents and plasmid DNA solutions. The company has a collaboration with Bio Usawa Biotechnology, Ltd. focusing on developing and manufacturing monoclonal antibodies in Sub-Saharan Africa to tackle oncology, diabetes-induced eye diseases, infectious diseases, and autoimmune conditions. It serves manufacturers of medications, vaccines, food, and chemicals, as well as research and development laboratories. The company was incorporated in 1978 and is headquartered in Aubagne, France. Sartorius Stedim Biotech S.A. is a subsidiary of Sartorius AG.

www.sartorius.com

10,483

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Recent News

View More

Performance Overview

Trailing total returns as of 10/30/2026, which may include dividends or other distributions. Benchmark is CAC 40 (^FCHI) .

YTD Return

SRTOY
4.82%
CAC 40 (^FCHI)
2.21%

1-Year Return

SRTOY
1.70%
CAC 40 (^FCHI)
2.30%

3-Year Return

SRTOY
27.23%
CAC 40 (^FCHI)
16.77%

5-Year Return

SRTOY
27.23%
CAC 40 (^FCHI)
16.68%

Earnings Trends

View More

Earnings Per Share

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q3 FY26
Revenue 762.1M
Earnings 95.5M
Profit Margin 12.53%

Q4

FY25

Q1

FY26

Q2

FY26

Q3

FY26

0
200M
400M
600M
8.0%
10.0%
12.0%

Statistics

View More

Valuation Measures

Annual
  • Market Cap

  • Enterprise Value

  • Trailing P/E

  • Forward P/E

  • PEG Ratio (current)

  • Price/Sales (ttm)

  • Price/Book (mrq)

  • Enterprise Value/Revenue

  • Enterprise Value/EBITDA

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    10.58%

  • Return on Assets (ttm)

    4.61%

  • Return on Equity (ttm)

    7.69%

  • Revenue (ttm)

    3.06B

  • Net Income Avi to Common (ttm)

    323.9M

  • Diluted EPS (ttm)

    0.39

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    172M

  • Total Debt/Equity (mrq)

    52.62%

  • Levered Free Cash Flow (ttm)

    270.52M

Company Insights

Research Reports

View More

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: